Cardiac stem cell research: regulation and practice in the UK and Germany

Debates on the regulation of stem cell research (SCR) tend to center on the governance of ethically contested stem cells (i.e. human embryonic), focus on the macro-dynamics of science development and the role of legislative bodies, and rely on documentary resources. They also largely ignore regulato...

Full description

Saved in:
Bibliographic Details
Published inInnovation (Abingdon, England) Vol. 25; no. 4; pp. 409 - 423
Main Authors Wilson-Kovacs, Dana, Hauskeller, Christine
Format Journal Article
LanguageEnglish
Published Abingdon Taylor & Francis Group 01.12.2012
Taylor & Francis Ltd
Subjects
cardiology
Cells
Clinical trials
Ethics
Europe
Federal Republic of Germany
Genetic Engineering
Germany
Governance
Heart disease
Innovation
Innovations
Legislative Bodies
Medical Research
Medical treatment
Medicine
Pharmaceutical industry
R&D
Regulation
Regulatory policy
regulatory space
Research & development
stem cell research
Stem cells
Therapy
United Kingdom
United Kingdom > UK
Germany
Online AccessGet full text

Cover

More Information
Summary:Debates on the regulation of stem cell research (SCR) tend to center on the governance of ethically contested stem cells (i.e. human embryonic), focus on the macro-dynamics of science development and the role of legislative bodies, and rely on documentary resources. They also largely ignore regulatory dynamics in adult SCR, where clinical trials have brought SCR closer to application. This article examines the contextual elaboration of novel medical treatment regulation in relation to stem cell therapies for heart repair using adult stem cells, in two European countries, the UK and Germany. It presents some of the challenges regulation poses in practice for both regulators and clinical teams, and discusses how the tension between the creation and maintenance of standards and the development of new treatments is understood by the regulators themselves. The conclusion evaluates the significance of regulatory practices in the production of new stem cell therapies in particular and innovative treatments more generally.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1351-1610
1469-8412
DOI:10.1080/13511610.2012.723881